title: Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy.
abstract: BACKGROUND
  We wished to evaluate the impact of S-1 combined with oxaliplatin (SOX regimen) as neoadjuvant chemotherapy on surgical outcomes after gastrectomy with D2 lymphadenectomy.
  
  
  METHODS
  From February 2012 to September 2013, 170 patients with American Joint Committee on Cancer (AJCC) stage II-III gastric cancer were assessed retrospectively. Eighty patients underwent neoadjuvant chemotherapy before radical gastrectomy, and 90 patients received surgical treatment with adjuvant chemotherapy. Patients received S-1 (80 mg/m(2)/day; days 1-14) and oxaliplatin (130 mg/m(2); day 1) as neoadjuvant or adjuvant chemotherapy, and this schedule was repeated every 3 weeks. Gastrectomy with D2 lymphadenectomy was standard therapy for each patient. Surgical outcomes between the two groups were analyzed statistically.
  
  
  RESULTS
  There was no significant difference in the total prevalence of complications between neoadjuvant and adjuvant groups (18.8% vs. 22.2%, P = 0.704). The most common postoperative complications were surgical site infection (6.5%) and gastrointestinal motility disorders (3.5%). The clinical response rate was 68.8%, and ten patients (12.5%) had a pathological complete response after neoadjuvant chemotherapy. The SOX regimen as neoadjuvant chemotherapy for AJCC stage II/III gastric cancer can be effective without increasing the risk of postoperative complications.
  
  
  CONCLUSIONS
  The SOX regimen could be a neoadjuvant chemotherapy for advanced gastric cancer worldwide in the future.
authors: Department of General Surgery, General Hospital of Chinese PLA, Beijing, 100853, China. vondolf@gmail.com.|Department of General Surgery, General Hospital of Tianjin Medical University, Tianjin, 300052, China. vondolf@gmail.com.
authors: Daofu
authors: D
authors: Feng
authors: Department of General Surgery, General Hospital of Chinese PLA, Beijing, 100853, China. harbi123@gmail.com.|Department of Surgery, Kiang Wu Hospital, Macao, China. harbi123@gmail.com.
authors: Meiha
authors: M
authors: Leong
authors: Department of General Surgery, General Hospital of Chinese PLA, Beijing, 100853, China. liting1987@sina.com.
authors: Ting
authors: T
authors: Li
authors: Department of General Surgery, General Hospital of Chinese PLA, Beijing, 100853, China. chenlinbj301@sina.com.
authors: Lin
authors: L
authors: Chen
authors: Department of General Surgery, General Hospital of Chinese PLA, Beijing, 100853, China. litbj301@vip.sina.com.
authors: Tao
authors: T
authors: Li
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D004338:Drug Combinations; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D005743:Gastrectomy / Q000401:mortality*; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D010094:Oxonic Acid / Q000008:administration & dosage; D011183:Postoperative Complications; D011379:Prognosis; D011446:Prospective Studies; D012074:Remission Induction; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D004338:Drug Combinations; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D005472:Fluorouracil
references: Ann Surg Oncol. 2014 Jan;21(1):213-9
references: 23838904
references: Eur J Surg Oncol. 2010 Jun;36(6):546-51
references: 20541062
references: Br J Surg. 2010 May;97(5):643-9
references: 20186890
references: Lancet Oncol. 2009 Sep;10(9):903-12
references: 19717092
references: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references: 21296855
references: Eur J Surg Oncol. 2000 Mar;26(2):168-71
references: 10744938
references: J Clin Oncol. 2006 May 10;24(14):2137-50
references: 16682732
references: Br J Surg. 2009 Sep;96(9):1015-22
references: 19644974
references: Cancer J. 2007 May-Jun;13(3):168-74
references: 17620766
references: Ann Oncol. 2015 Jan;26(1):141-148
references: 25316259
references: N Engl J Med. 2006 Jul 6;355(1):11-20
references: 16822992
references: Eur J Cancer. 2009 Jan;45(2):228-47
references: 19097774
references: Cancer. 2003 Oct 1;98(7):1521-30
references: 14508841
references: Ann Oncol. 2010 May;21(5):1001-5
references: 19875759
references: Cancer Chemother Pharmacol. 2011 Jun;67(6):1423-8
references: 20809123
references: Am J Clin Oncol. 2017 Feb;40(1):17-21
references: 24662266
references: Lancet. 2012 Dec 15;380(9859):2095-128
references: 23245604
references: Ann Surg Oncol. 2013 Nov;20(12):3905-11
references: 23807661
references: Br J Surg. 1997 Nov;84(11):1567-71
references: 9393281
references: N Engl J Med. 2007 Nov 1;357(18):1810-20
references: 17978289
references: World J Surg Oncol. 2011 Sep 26;9:110
references: 21942969
references: J Clin Oncol. 2011 May 1;29(13):1715-21
references: 21444866
references: Invest New Drugs. 2012 Feb;30(1):350-6
references: 20706861
references: Gastric Cancer. 2014 Apr;17(2):213-25
references: 24048758
references: N Engl J Med. 2008 Jul 31;359(5):453-62
references: 18669424
references: J Surg Oncol. 2012 May;105(6):535-41
references: 22006649
references: J Clin Oncol. 2011 Nov 20;29(33):4387-93
references: 22010012
references: Gastric Cancer. 2008;11(2):96-102
references: 18595016
references: Eur J Cancer. 2012 Mar;48(4):518-26
references: 22243774
references: Lancet Oncol. 2008 Mar;9(3):215-21
references: 18282805
references: Cancer Chemother Pharmacol. 2010 Feb;65(3):473-80
references: 19551382
references: World J Surg. 2000 Sep;24(9):1130-5; discussion 1135-6
references: 11036293
references: J Clin Oncol. 2006 May 10;24(14):2188-96
references: 16682738
references: Hepatogastroenterology. 2012 Mar-Apr;59(114):649-53
references: 22328264
references: Gastric Cancer. 1998 Dec;1(1):10-24
references: 11957040